- Home
- ROIV vs EIX Comparison
ROIV vs EIX Comparison
Compare ROIV & EIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | EIX |
|---|---|---|
| Founded | 2014 | 1886 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 27.8B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EIX |
|---|---|---|
| Price | $35.36 | $69.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 13 |
| Target Price | $28.94 | ★ $72.09 |
| AVG Volume (30 Days) | ★ 4.8M | 2.8M |
| Earning Date | 05-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | N/A | ★ 248.94 |
| EPS | N/A | ★ 1.37 |
| Revenue | $8,260,000.00 | ★ $19,317,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $744.61 | $3.17 |
| P/E Ratio | ★ N/A | $49.36 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $11.54 | $52.00 |
| 52 Week High | $37.00 | $81.62 |
Technical Indicators
Market Signals| Indicator | ROIV | EIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 35.98 |
| Support Level | $33.01 | $66.31 |
| Resistance Level | $36.35 | $72.89 |
| Average True Range (ATR) | 1.26 | 2.19 |
| MACD | 0.04 | -1.17 |
| Stochastic Oscillator | 63.92 | 16.16 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EIX Edison International
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.